Insider · CIK 0001701440

Walker Luke Nathaniel

Reports to the SEC for 4 companies · PHILADELPHIA, PA

sec.gov

Transactions

Companies

Filings

CIK

0001701440

Forms 4 and 5

Insider transactions

34 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-24	CNTXContext Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+45K sh	—	—	45,000
2026-06-16	ZNTLZentalis Pharmaceuticals, Inc.A Award	Director	AAward	+57.1K sh	—	—	201,384
2025-06-17	ZNTLZentalis Pharmaceuticals, Inc.A Award	Director	AAward	+57.6K sh	—	—	144,284
2025-06-12	CNTXContext Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+124K sh	—	—	123,500
2025-01-31	ZNTLZentalis Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+14.2K sh	$1.76	+$25K	86,681
2024-09-04	CNTXContext Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+19.3K sh	—	—	19,315
2024-05-24	ZNTLZentalis Pharmaceuticals, Inc.A Award	Director	AAward	+72.5K sh	—	—	72,481
2024-03-11	Harpoon Therapeutics, Inc.D Disposition to Issuer	Chief Medical Officer	DDisposition to Issuer	−135K sh	—	—	0
2024-03-11	Harpoon Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Chief Medical Officer	DDisposition to Issuer	−30.5K sh	—	—	0
2024-03-11	Harpoon Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Chief Medical Officer	DDisposition to Issuer	−10K sh	—	—	0
2024-01-07	Harpoon Therapeutics, Inc.A Award	Chief Medical Officer	AAward	+115K sh	—	—	135,000
2023-11-26	Harpoon Therapeutics, Inc.A Award	Chief Medical Officer	AAward	+20K sh	—	—	20,000
2023-01-24	Harpoon Therapeutics, Inc.Employee Stock Option (right to buy)A Award	Chief Medical Officer	AAward	+100K sh	—	—	100,000
2022-10-03	Harpoon Therapeutics, Inc.Employee Stock Option (right to buy)A Award	Chief Medical Officer	AAward	+305K sh	—	—	305,000
2018-03-09	Cascadian Therapeutics, Inc.U Disposition from Tender	SVP, Clinical Development	UDisposition from Tender	−10.3K sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Stock Option (Right to buy)D Disposition to Issuer	SVP, Clinical Development	DDisposition to Issuer	−2,500 sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Stock Option (Right to buy)D Disposition to Issuer	SVP, Clinical Development	DDisposition to Issuer	−334 sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Stock Option (Right to buy)D Disposition to Issuer	SVP, Clinical Development	DDisposition to Issuer	−1,250 sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Stock Option (Right to buy)D Disposition to Issuer	SVP, Clinical Development	DDisposition to Issuer	−2,500 sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Stock Option (Right to buy)D Disposition to Issuer	SVP, Clinical Development	DDisposition to Issuer	−1,250 sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Stock Option (Right to buy)D Disposition to Issuer	SVP, Clinical Development	DDisposition to Issuer	−5,834 sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Stock Option (Right to buy)D Disposition to Issuer	SVP, Clinical Development	DDisposition to Issuer	−8,334 sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Stock Option (Right to buy)D Disposition to Issuer	SVP, Clinical Development	DDisposition to Issuer	−20.8K sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Stock Option (Right to buy)D Disposition to Issuer	SVP, Clinical Development	DDisposition to Issuer	−35.1K sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Stock Option (Right to buy)D Disposition to Issuer	SVP, Clinical Development	DDisposition to Issuer	−50K sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	SVP, Clinical Development	DDisposition to Issuer	−7,800 sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	SVP, Clinical Development	DDisposition to Issuer	−12K sh	—	—	0
2018-03-09	Cascadian Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	SVP, Clinical Development	DDisposition to Issuer	−130K sh	—	—	0
2018-02-01	Cascadian Therapeutics, Inc.Restricted Share Unit (RSU)A Award	SVP, Clinical Development	AAward	+130K sh	—	—	130,000
2018-01-11	Cascadian Therapeutics, Inc.M Exercise/Conversion	SVP, Clinical Development	MExercise/Conversion	+1,950 sh	—	—	5,940
2018-01-11	Cascadian Therapeutics, Inc.F Tax Payment	SVP, Clinical Development	FTax Payment	−637 sh	$3.92	−$2,497.04	5,303
2018-01-11	Cascadian Therapeutics, Inc.Restricted Share Unit (RSU)M Exercise/Conversion	SVP, Clinical Development	MExercise/Conversion	−1,950 sh	—	—	5,850
2017-09-18	Cascadian Therapeutics, Inc.Stock Option (right to buy)A Award	SVP, Clinical Development	AAward	+50K sh	—	—	50,000
2017-09-18	Cascadian Therapeutics, Inc.Restricted Share Unit (RSU)A Award	SVP, Clinical Development	AAward	+12K sh	—	—	12,000

Recent filings

Accepted (ET)
Jun 264
Walker Luke Nathaniel0001628280-26-045775
SEC(opens sec.gov)
Jun 184
Walker Luke Nathaniel0001701440-26-000004
SEC(opens sec.gov)
Jun 184
Walker Luke Nathaniel0001725160-25-000137
SEC(opens sec.gov)
Jun 124
Walker Luke Nathaniel0001842952-25-000074
SEC(opens sec.gov)
Feb 44
Walker Luke Nathaniel0001725160-25-000029
SEC(opens sec.gov)
Sep 54
Walker Luke Nathaniel0001842952-24-000077
SEC(opens sec.gov)
May 294
Walker Luke Nathaniel0001725160-24-000123
SEC(opens sec.gov)
Mar 114
Walker Luke Nathaniel0000950170-24-029445
SEC(opens sec.gov)
Jan 94
Walker Luke Nathaniel0000950170-24-003369
SEC(opens sec.gov)
Nov 284
Walker Luke Nathaniel0001209191-23-056810
SEC(opens sec.gov)
Jan 264
Walker Luke Nathaniel0001209191-23-005038
SEC(opens sec.gov)
Oct 44
Walker Luke Nathaniel0001209191-22-052200
SEC(opens sec.gov)
Mar 134
Walker Luke Nathaniel0000899243-18-007310
SEC(opens sec.gov)

Companies

Address

2001 MARKET STREET SUITE 3915 UNIT #15

PHILADELPHIA, PA, 19103